Miriam Klausberger

Miriam Klausberger is a researcher at the Institute of Molecular Biotechnology within the Department of Biotechnology and Life Sciences at the University of Natural Resources and Life Sciences, Vienna (BOKU). She has held postdoctoral and project leadership roles, including co-PI on FWF-funded projects related to SARS-CoV-2 and vaccine development. Her research spans virology, molecular biotechnology, and vaccine design, with a focus on virus-like particles and antigen purification.

Her research interests include vaccine development, bioseparation techniques, SARS-CoV-2 antigen design, and influenza VLPs. She investigates both fundamental virological mechanisms and applied biotechnological solutions for diagnostics and therapeutics. Her work emphasizes interdisciplinary collaboration and translational outcomes.

The most recent articles highlight a strong trend in diagnostic antigen engineering for SARS-CoV-2 serotesting, purification of VLPs, and evaluation of vaccine-induced immune responses. Keywords across these works include virology, bioprocessing, glycobiology, and immunology, reflecting a multidisciplinary approach to vaccine and diagnostic development.

Scientific awards received include:

• BOKU Inventor of the Year (2023)
• HOUSKA Award, 3rd place (2021)
• BOKU Talent Award (2016)
• BOKU Innovation Award, 3rd place (2015)
• Raiffeisen Science and Innovation Publication Award (2014)
• INITS Award in Life Sciences, 2nd place (2011)

Miriam Klausberger has been actively involved in research projects funded by the FWF, serving as co-PI and project leader. She has advised university theses and collaborated with institutions such as the Medical University of Vienna (MUW), JKU Linz, AIT, and international labs. Her work demonstrates strong grant acquisition and collaborative research capabilities.

She is part of research teams focused on molecular biotechnology and vaccine development at BOKU, with collaborations extending to industrial biotechnology centers like acib and AIT. Her work involves interdisciplinary teams in virology, protein engineering, and analytical biotechnology.